Expertise in
13
conditions

Dr. James M. Andry

Sleep Medicine | Pulmonary Medicine
James M Andry MD PA
5290 Medical Dr, Suite A, 
San Antonio, TX 
Accepting New Patients
Offers Telehealth
43 Years of Experience
Expertise in
13
conditions
James M Andry MD PA
5290 Medical Dr, Suite A, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Andry is a Sleep Medicine specialist and a Pulmonary Medicine provider in San Antonio, Texas. Dr. Andry has been practicing medicine for over 43 years is highly rated in 13 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Narcolepsy, Excessive Daytime Sleepiness, and Drowsiness. Dr. Andry is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Sleep Medicine
Pulmonary Medicine
Licenses
Specialist in TX
Languages Spoken
English
Arabic
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

JAMES M ANDRY MD PA
5290 Medical Dr, Suite A, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR
Enrollment Status: Completed
Publish Date: October 02, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
Study Using Negative Pressure to Reduce Apnea (SUPRA)
Study Using Negative Pressure to Reduce Apnea (SUPRA)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
A 6-Month Multicenter, Open-Labelled Extension of the Clinical Trial NLS-1021 in Narcoleptic Patients With and Without Cataplexy
Enrollment Status: Completed
Publish Date: March 13, 2023
Intervention Type: Drug
Study Drug: Mazindol
Study Phase: Phase 2
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Phase 2, Placebo-Controlled, Parallel Group Dose-Finding Study to Evaluate the Efficacy and Safety of Three Dose Levels of AD036 in Adults With Obstructive Sleep Apnea
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy
A Four-week, Double-blind, Placebo-controlled, Randomized, Multicenter, Parallel-group Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in Adults for the Treatment of Narcolepsy
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Drug: Mazindol
Study Phase: Phase 2
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device
A Study to Assess the Frequency and Characteristics of Wake and Sleep State Transitions Over Multiple Nights in Subjects With Narcolepsy Type 1 Compared With Healthy Subjects Using a Portable Electroencephalogram Device
Enrollment Status: Completed
Publish Date: May 07, 2021
Intervention Type: Device
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
Enrollment Status: Completed
Publish Date: November 12, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2
Enrollment Status: Completed
Publish Date: January 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
VISC-Q Trial (Validation of an Online Sleep Characterization Questionnaire)
VISC-Q Trial (Validation of an Online Sleep Characterization Questionnaire)
Enrollment Status: Completed
Publish Date: September 21, 2018
Intervention Type: Other
View 12 Less Clinical Trials

3 Total Publications

Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.
Journal: Annals of the American Thoracic Society
Published: May 01, 2020
Similar Doctors
Expertise in
8
conditions
Dr. Anoop M. Nambiar
Pulmonary Medicine | Intensive Care Medicine
Expertise in
8
conditions
Dr. Anoop M. Nambiar
Pulmonary Medicine | Intensive Care Medicine

The University Of Texas Health Science Center At San Antonio

4502 Medical Dr, 
San Antonio, TX 
 (0.8 miles away)
210-358-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anoop Nambiar is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in San Antonio, Texas. Dr. Nambiar is highly rated in 8 conditions, according to our data. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Pulmonary Fibrosis. Dr. Nambiar is currently accepting new patients.

Expertise in
6
conditions
Dr. Marcos I. Restrepo
Pulmonary Medicine
Expertise in
6
conditions
Dr. Marcos I. Restrepo
Pulmonary Medicine
7400 Merton Minter Blvd, 
San Antionio, TX 
 (0.6 miles away)
210-617-5300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marcos Restrepo is a Pulmonary Medicine provider in San Antionio, Texas. Dr. Restrepo is highly rated in 6 conditions, according to our data. His top areas of expertise are Pneumonia, COVID-19, Bronchiectasis, Lung Transplant, and Endoscopy. Dr. Restrepo is currently accepting new patients.

Expertise in
3
conditions
Dr. David A. Schenk
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
3
conditions
Dr. David A. Schenk
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Pulmonary Consultants Of San Antonio PA

10007 Huebner Rd, Suite 402, 
San Antonio, TX 
 (1.9 miles away)
210-692-0361
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Schenk is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in San Antonio, Texas. Dr. Schenk is highly rated in 3 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Drowsiness, Excessive Daytime Sleepiness, and REM Behavior Disorder. Dr. Schenk is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Andry's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile